A Phase 3, Open-Label, Multicenter Study of a 6-Month Pre-Mixed Depot Formulation of Leuprolide Mesylate in Advanced Prostate Cancer Patients
World Journal of Urology - Germany
doi 10.1007/s00345-019-02741-7
Full Text
Open PDFAbstract
Available in full text
Categories
Date
April 3, 2019
Authors
Publisher
Springer Science and Business Media LLC